(2S)-2,3-dipentoxypropan-1-ol;phosphono dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: (2S)-2,3-dipentoxypropan-1-ol;phosphono dihydrogen phosphate
• 化学式: C13H32O10P2
• 分子量: 410.33
• InChiKey: KGQXHSVKHAFPIC-ZOWNYOTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.95
• 重原子数：
  25
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  163
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• EP2908839A2
  申请人：——

  公开号：EP2908839A2

  公开（公告）日：2015-08-26
• METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME
  申请人：Stealth Biotherapeutics Corp

  公开号：EP2961420A1

  公开（公告）日：2016-01-06
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF SENGERS SYNDROME
  申请人：Stealth BioTherapeutics Inc.

  公开号：EP3890765A1

  公开（公告）日：2021-10-13
• [EN] METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH<br/>[FR] MÉTHODES POUR LA RÉDUCTION DE RISQUES ASSOCIÉS À UNE INSUFFISANCE CARDIAQUE ET DE FACTEURS ASSOCIÉS À CELLE-CI
  申请人：STEALTH PEPTIDES INT INC

  公开号：WO2014066419A2

  公开（公告）日：2014-05-01

  The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to increase expression of Taz1 and/or increase mK ATP activity in subjects in need thereof.
• [EN] METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME<br/>[FR] MÉTHODES ET COMPOSITIONS DE PRÉVENTION OU DE TRAITEMENT DU SYNDROME DE BARTH
  申请人：STEALTH PEPTIDES INT INC

  公开号：WO2014134554A1

  公开（公告）日：2014-09-04

  The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.